JIC
MRTX

Joel Isaacson & Co’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Joel Isaacson & Co’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-2,500
Closed -$12K – 564
2016
Q4 		$12K Hold
2,500
– – ﹤0.01% 484
2016
Q3 		$17K Buy
2,500
+1,000
+67% +$5.32K ﹤0.01% 488
2016
Q2 		$8K Buy
+1,500
New +$23.9K ﹤0.01% 565

Other funds holding MRTX

AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Joel Isaacson & Co's MRTX Position: Q1 2017 in Review

Joel Isaacson & Co sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2017, closing a stake of 2,500 shares — an estimated $12K sold.

Joel Isaacson & Co first reported a position in MRTX in Q2 2016 and held it in 3 quarters. The position peaked at $17K in Q3 2016. 64 funds tracked by Wall St. Rank hold MRTX as of Q1 2017.

  • Joel Isaacson & Co reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2017 after selling out during the quarter.
  • Joel Isaacson & Co sold 2,500 Mirati Therapeutics, Inc. Common Stock shares in Q1 2017, an estimated $12K.
  • Joel Isaacson & Co first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2016 and held it in 3 quarters.
  • Joel Isaacson & Co's Mirati Therapeutics, Inc. Common Stock position peaked at $17K in Q3 2016.
  • 64 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2017.

Based on Joel Isaacson & Co's 13F filing for Q1 2017, filed 5 May 2017.